Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 10/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869868 | 0.94 | ROCK2 (0.43) | ROCK2TEKKDREPHB4F10 | |
| SCHEMBL14003483 | 0.77 | ROCK2 (0.59) | ROCK2TEKKDREPHB4KHK | |
| SCHEMBL119410 | 0.76 | KMT2A (0.49) | EPHX2OPRD1KCNH2MEN1CYP1A2 | |
| SCHEMBL4873237 | 0.72 | HSD11B1 (0.43) | OPRD1KCNH2MEN1KMT2A | |
| SCHEMBL20882116 | 0.70 | TEK (0.55) | ROCK2TEKKDREPHB4EGFR | |
| SCHEMBL8213573 | 0.70 | TEK (0.55) | ROCK2TEKKDREPHB4EGFR | |
| SCHEMBL4870754 | 0.69 | TET3 (0.50) | CYP2D6KMT2A | |
| SCHEMBL22960725 | 0.69 | KMT2A (0.42) | EPHX2OPRD1MEN1CYP3A4CYP2C9 | |
| SCHEMBL3015079 | 0.69 | KMT2A (0.42) | EPHX2OPRD1KCNH2MEN1KMT2A | |
| SCHEMBL30089214 | 0.69 | KMT2A (0.42) | EPHX2OPRD1MEN1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1814552-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | Astex Therapeutics Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051290-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | ROCK2 594/4885TEK 2388/4885KDR 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.